|
|
Article: Dendreon's Trp-p8 Gene Platform Garners $110M Genentech Deal.
- Article from:
- BIOWORLD Today
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Washington Editor
Dendreon Corp. could gain more than $110 million in a deal with Genentech Inc. to develop monoclonal antibodies, small molecules and other products from Dendreon's preclinical Trp-p8 gene platform.
The Street viewed the deal as favorable for Dendreon (NASDAQ:DNDN), whose stock shot up $1.06, or 34.4 percent, Tuesday to close at $4.14. Genentech's stock (NYSE:DNA) closed at $34.15, down $1.30.
Tuesday's hefty collaboration comes on the heels of Dendreon's statement last week that Phase III data for Provenge in end-stage prostate cancer patients show the vaccine works well in men with a Gleason score (measure of the ...
Related newspaper, magazine, and journal articles:
|
|
Article: DENDREON TIGHTENS FOCUS OF PHASE III PROVENGE TRIAL.
BIOWORLD Today;
December 6, 2002 ;
700+ words
... ... less. (See BioWorld Today, Aug. 12 ... David Urdal, Dendreon's president ... officer, told BioWorld Today. A Gleason score ... late October, Dendreon apparently satisfied ... 7 men. (See BioWorld Today, Oct. 29 ...
|
|